Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks quality of life in myeloma patients on selinexor combo

NCT ID NCT05954780

Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study follows 75 people with relapsed or refractory multiple myeloma who are already taking selinexor combined with bortezomib and dexamethasone. Researchers will track quality of life, side effects, and how the treatment works in everyday medical practice. The goal is to provide real-world evidence that complements earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
selinexor (Nexpovio®) combined with bortezomib and dexamethasone
What this could lead to
If successful, this study could provide doctors with better information on how to manage side effects and improve quality of life for people with multiple myeloma.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove the treatment works better than other options. Results may vary widely among participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

75 people

The number who actually took part.

Started

Jun 2023

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥18 years old) with relapsed or refractory multiple myeloma and decision for treatment with selinexor in combination with bortezomib and dexamethasone (SVd) in ≥2nd therapy line

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Relapsed or refractory multiple myeloma * Indication and decision for ≥2nd-line treatment with selinexor in combination with bortezomib and dexamethasone according to current selinexor SmPC as assessed by the treating physician * Treatment decision before inclusion into this non-interventional study * Willingness and ability to participate in the electronic patient-reported outcome (ePRO) module and answering of questionnaires * Age ≥18 years * Signed and dated informed consent form * Inclusion before start of treatment (prospective inclusion) Exclusion Criteria: * Contraindications according to selinexor SmPC for patients with MM * Participation in an interventional clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Gemeinschaftspraxis für Hämatologie und Onkologie GbR

    Ravensburg, Baden-Wurttemberg, 88212, Germany

  • Medizinische Universität Wien, Universitätsklinik für Innere Medizin I

    Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.